Phaseline

Companies › Myosin Therapeutics

Myosin Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Feb 2032.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MT-125
unclear - acts on cancer cells in the brain to destroy them and may enhance radiotherapy e
–Phase 1Glioblastoma (GBM)Feb 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07185880MT-125Phase 1Glioblastoma (GBM)OncologyFeb 2032

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.